№ files_lp_4_process_3_073858
File format: docx
Character count: 1719
File size: 18 KB
Supplementary scientific figure legends describing experimental conditions, molecular analyses, and treatment responses in prostate cancer cell lines and xenograft models involving enzalutamide resistance and BET bromodomain inhibition.
Year:
Not specified
Field:
Molecular Biology; Cancer Research
Disease Focus:
Prostate Cancer
Experimental Models:
VCaP cells; LNCaP cells; LNCaP-AR cells; Patient-Derived Xenograft (PDX) models
Key Compounds:
Enzalutamide; JQ1; OTX-015; I-BET762; DMSO
Experimental Methods:
Xenograft mouse experiments; RT-qPCR; ChIP-seq; Western blot; Cell viability assay
Measured Genes / Proteins:
AR; AR-V7; MYC; GR; SLC45A3; BRD2; BRD3; BRD4; SRSF1; U2AF1; ERG; H3K27ac; Med1
Statistical Methods:
Two-tailed Student’s t-test
Treatment Regimen:
30 mg/kg enzalutamide, 5 days per week for 5 weeks in xenografted mice
Sample Size:
Vehicle-treated mice (n=20); Enzalutamide-treated mice (n=20); Four wells per condition in cell viability assays
Source Type:
Supplementary material to a scientific research publication
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / City:
Australia
Subject:
Pharmaceutical submission
Document Type:
Submission for listing
Organization / Institution:
Astellas Pharma Australia Pty Ltd
Author:
Astellas Pharma Australia Pty Ltd
Target Audience:
Medical practitioners, regulatory bodies
Effective Period:
Since April 2021
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2025
Organization:
NICE Technology Appraisal Committee
Document type:
Interests Register
Region:
United Kingdom
Subject:
Conflicts of interest in health technology appraisal
Participants:
Peter Wheatley Price, Warren Linley, David McAllister, Professor Suneil Jain, Rhiannon Owen, Holly Knight
Date of publication:
TBC
Relevant period:
2025
Financial interests:
Pfizer, AstraZeneca, Bayer, Astellas, Johnson & Johnson, Boston Scientific, Teleflex, Accord, Molli Surgical, BXT Nanotherapy
Professional roles:
Committee members, clinical expert, patient expert
Access to trial data:
Yes
Appraisal ID:
4004
Record type:
Committee disclosures
Year:
2015
Region / City:
Australia
Theme:
Oncology
Document Type:
Pharmaceutical Submission
Organization / Institution:
Department of Human Services
Author:
Not specified
Target Audience:
Medical professionals, prescribers
Period of Validity:
Ongoing
Approval Date:
November 2015
Date of Amendments:
Not specified
Treatment Phase:
Initial and Continuing
Condition:
Metastatic Castration-Resistant Prostate Cancer
PBS Indication:
Castration-resistant metastatic carcinoma of the prostate
Clinical Criteria:
Patients who have not received prior docetaxel treatment
Administrative Advice:
Queries directed to the Department of Human Services
Price:
$3,701.18 for maximum quantity
Proprietary Name and Manufacturer:
Xtandi, Astellas Pharma
Category / Program:
General Schedule (Code GE)
Prescriber Type:
Medical practitioners, nurse practitioners, optometrists, midwives
Treatment Criteria:
Not to be used in combination with chemotherapy
Context:
A pharmaceutical submission for the inclusion of enzalutamide on the PBS for asymptomatic metastatic castration-resistant prostate cancer patients who have not previously had docetaxel treatment.
Year:
2019
Region / City:
United Kingdom
Topic:
Gambling Dispute
Document Type:
Written Evidence
Author:
Richard Powell
Target Audience:
UK Parliament Committee
Period of Validity:
Ongoing
Approval Date:
24 July 2019
Year:
2026
Choreographers:
Mackenzie Keister (USA) & Krista Young (USA)
Music:
Bet On It - Troy
Level:
Advanced
Wall:
2
Count:
208
Style:
Line Dance
Target Audience:
Dancers, Dance Instructors
Event:
Dance Workshop/Performance
Duration:
3-5 minutes
Phrasing:
ABB ABB CBB
Date of Creation:
January 2026
Date of Revision:
N/A
Year:
2009
Location:
San Antonio, Texas, USA
Institution:
Esnoga Bet Emunah
Type:
Religious calendar and Torah commentary
Audience:
Congregation members and Torah scholars
Reading Cycle:
First Year of the Triennial and Shmita Cycles
Candle Lighting Times:
Listed for multiple global cities
Torah Portion:
VaYishlach (B’Resheet 32:4 – 33:17)
Additional Texts:
Ashlamatah Obadiah 1:1-9 + 21, Pirke Abot II:11, Psalm 27, N.C. Jude 24-25
Commentaries:
Rashi & Targum Pseudo Jonathan
Contributors:
Named donors and community members
Year:
2026
Region / City:
Global / English-speaking context
Theme:
Literature study; narrative analysis
Document Type:
Study guide / Discussion questions
Author:
Unknown compiler
Target Audience:
Students, educators, literary analysts
Source Text:
"The Bet" by Anton Chekhov
Literary Focus:
Plot, character development, moral and philosophical questions
Topics Covered:
Flashback, setting, conflict, character motivation, moral interpretation, literary transformation, symbolism
Related Concepts:
Capital punishment vs. life imprisonment, human desire, personal transformation
Year:
2003
Region / City:
Unknown
Topic:
Gender Role Reversal, Humiliation, Transformation
Document Type:
Story
Author:
Susie Frillikins
Target Audience:
Adults, interested in fetish literature
Period of validity:
Not applicable
Approval Date:
Jul/10/2003
Modification Date:
Not specified
Year:
2019
Region / City:
Australia
Topic:
Pharmaceutical Benefits Scheme, PD-(L)1 inhibitors, non-small cell lung cancer (NSCLC)
Document type:
Meeting minutes
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Professor Andrew Wilson (PBAC Chair)
Target audience:
Stakeholders in the healthcare and pharmaceutical industry
Period of validity:
2019 and onwards
Date of approval:
February 2019
Date of amendments:
Not specified
Year:
2021
Region / city:
N/A
Document type:
Research supplementary materials
Organization / institution:
University of North Carolina
Author:
Ling Xie, Ryan N. Sheehy, Yan Xiong, Adil Muneer, John A. Wrobel, Kwang-Su Park, Julia Velez, Jing Liu, Yan-Jia Luo, Ya-Dong Li, Luis Quintanilla, Yongyi Li, Chongchong Xu, Mohanish Deshmukh, Zhexing Wen, Jian Jin, Juan Song, Xian Chen
Target audience:
Researchers in neuroscience, pharmacology, and precision medicine
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Year:
2013
Region / City:
Leeds, Yorkshire and The Humber
Theme:
Clinical trials, Chronic Kidney Disease
Document type:
Research study protocol
Organization:
University of Birmingham Clinical Trials Unit, Hull and East Yorkshire Hospitals NHS Trust
Author:
Prof Sunil Bhandari
Target audience:
Healthcare professionals, nephrologists, researchers
Period of validity:
3 years
Approval date:
2013
Change date:
N/A
Study reference number:
11/30/07
Ethics committee reference:
13/YH/0394
EudraCT number:
2013-003798-82
Sponsor:
Hull and East Yorkshire Hospitals NHS Trust
Funding source:
Efficacy and Mechanism Evaluation (EME) programme, National Institute for Health Research (NIHR), Medical Research Council (MRC)
Note:
Contextual description
Year:
2026
Region / City:
Global
Topic:
Pharmacogenetics, Antidepressants
Document Type:
Guideline
Organization / Institution:
Clinical Pharmacogenetics Implementation Consortium (CPIC)
Authors:
Chad A. Bousman, James M. Stevenson, Laura B. Ramsey, Katrin Sangkuhl, J. Kevin Hicks, Jeffrey R. Strawn, Ajeet B. Singh, Gualberto Ruaño, Daniel J. Mueller, Evangelia Eirini Tsermpini, Jacob T. Brown, Gillian C. Bell, J. Steven Leeder, Andrea Gaedigk, Stuart A. Scott, Teri E. Klein, Kelly E. Caudle, Jeffrey R. Bishop
Target Audience:
Healthcare professionals, geneticists, pharmacologists
Effective Period:
Ongoing
Approval Date:
2026
Modification Date:
Not specified
Year:
2026
Region / City:
Southampton, U.K.; Newcastle upon Tyne, U.K.; Cambridge, U.K.
Subject:
Biochemistry, Cancer Research
Document Type:
Research Article
Organization / Institution:
University of Southampton, Newcastle University, AstraZeneca
Author:
Eliot L. Osher, Francisco Castillo, Nagarajan Elumalai, Michael J. Waring, Garry Pairaudeau, Ali Tavassoli
Target Audience:
Researchers, Scientists, Medical Professionals
Duration:
Ongoing
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / City:
Global
Topic:
Research
Document Type:
Technical Data Sheet
Organization / Institution:
Abcam
Author:
Abcam
Target Audience:
Researchers, Laboratory Technicians
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Description:
Technical data sheet detailing the usage and protocol for the COX2 Inhibitor Screening Kit (Fluorometric), a product intended for high-throughput screening of COX-2 inhibitors in research laboratories.
Year:
2023
Region / city:
Benha, Al-Ahsa, Sohag, Alqurayat
Subject:
Corrosion inhibition, Surfactants, Electrochemical Analysis
Document Type:
Research Paper
Organization / Institution:
Benha University, King Faisal University, Sohag University, Jouf University
Author:
Mohamed A. Abo-Riya, Kamal A. Soliman, Hany M. Abd El-Lateef, Ahmed H. Tantawy, Salah Eid
Target Audience:
Researchers, Academics, Engineers in Materials Science and Chemistry
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Context:
A research paper examining the synthesis, properties, and performance of imine surfactants as corrosion inhibitors for carbon steel in acidic solutions.
Year:
2023
Region / City:
Ann Arbor, MI, USA
Topic:
Cancer Research, Glycolytic Metabolism, Cell Migration
Document Type:
Research Article
Organization:
University of Michigan
Authors:
Brock Humphries, Johanna M. Buschhaus, Yu-Chih Chen, Henry R. Haley, Tonela Qyli, Benjamin Chiang, Nathan Shen, Shrila Rajendran, Alyssa Cutter, Yu-Heng Cheng, Yu-Ting Chen, Jason Cong, Phillip C. Spinosa, Euisik Yoon, Kathryn E. Luker, Gary D. Luker
Target Audience:
Researchers, Medical Professionals, Oncology Specialists
Period of Action:
N/A
Date of Approval:
N/A
Date of Revisions:
N/A
Country:
United Kingdom
Topic:
Hereditary angioedema and acquired C1 inhibitor deficiency
Document type:
Medical research article
Study type:
National survey
Authors:
Patrick FK Yong; Tanya Coulter; Tariq El-Shanwany; Tomaz Garcez; Scott Hackett; Rashmi Jain; Sorena Kiani-Alikhan; Ania Manson; Sadia Noorani; Catherine Stroud; Christine Symons; Ravishankar Sargur; Cathal Steele; Hana Alachkar; Ariharan Anantharachagan; Peter D Arkwright; Jolanta Bernatoniene; Malini Bhole; Lindsay Brown; Matthew Buckland; Siobhan Burns; Charu Chopra; James Darroch; Elizabeth Drewe; Jillian Edmonds; Anjali Ekbote; Shuayb Elkhalifa; Sarah Goddard; Dorothea Grosse-Kreul; Padmalal Gurugama; Rosie Hague; Richard Herriot; Archana Herwadkar; Stephen M Hughes; Laura Jones; Sara Lear; Elizabeth McDermott; Sai Hurng Kham Murng; Arthur Price; Vyanka Redenbaugh; Alex Richter; Andrew Riordan; Fiona Shackley; Julia Stichbury; Debbie Springett; Michael D Tarzi; Moira Thomas; Pavaladurai Vijayadurai; Austen Worth
Institutions:
Multiple NHS trusts and university hospitals across England, Scotland, Wales, and Northern Ireland
Corresponding author:
Patrick FK Yong
Corresponding institution:
Frimley Health NHS Foundation Trust
Methodology:
Questionnaire survey of specialist centres managing hereditary angioedema and acquired C1 inhibitor deficiency
Number of participating centres:
37
Patient population:
Individuals with HAE-1/2, HAE with normal C1 inhibitor, and acquired C1 inhibitor deficiency
Sample size:
1265 patients
Medical conditions studied:
Hereditary angioedema; acquired C1 inhibitor deficiency
Key treatments mentioned:
Danazol; C1 inhibitor replacement therapy; icatibant; tranexamic acid
Funding source:
Unrestricted grant from Pharming
Keywords:
hereditary angioedema; acquired C1 inhibitor deficiency; epidemiology; demographics; treatment modalities; United Kingdom
Year:
2026
Research Institution:
[Not specified in document]
Cell Lines:
PEO1, TOV21G, UWB1.289
Genes Studied:
BRCA1, BRCA2, FZD10, ALKBH5, FTO, METTLE3, METTLE14, YTHDF2, HuR, IGF2BP2
Drugs:
Olaparib, Niraparib, Rucaparib, XAV939
Experimental Methods:
Immunoblotting, qRT-PCR, RNA electrophoresis, shRNA knockdown, lentiviral infection, HR and NHEJ reporter assays, apoptosis assays, mouse xenograft models
Target Pathways:
Wnt signaling, DNA repair pathways (HR and NHEJ)
Data Analysis Tools:
NIH ImageJ, statistical analysis via two-tailed t-test
Supplement Type:
Figure legends for supplementary data in molecular biology research
End Date of Experimentation:
Not specified
Year:
2018
Region:
Australia
Subject:
PD-1 and PD-L1 checkpoint inhibitor immunotherapies
Document Type:
Submission Template
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Intended Audience:
Patients, healthcare providers, researchers, pharmaceutical industry, government bodies
Submission Deadline:
29 June 2018
Contact Information Required:
Yes
Confidentiality Note:
Commercial-in-confidence or personal information to be redacted before publication
Format:
Electronic submission in Microsoft Word or text-based format
Questions Covered:
Advantages, disadvantages, unmet clinical need, evidence requirements, cost-effectiveness, subsidy pricing, biomarker considerations, extrapolation across medicines and cancer types, rare cancers, follow-up actions, clinical trials, international models